356 related articles for article (PubMed ID: 32315234)
21. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.
Arai Y; Totoki Y; Hosoda F; Shirota T; Hama N; Nakamura H; Ojima H; Furuta K; Shimada K; Okusaka T; Kosuge T; Shibata T
Hepatology; 2014 Apr; 59(4):1427-34. PubMed ID: 24122810
[TBL] [Abstract][Full Text] [Related]
22. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers.
Chan-On W; Nairismägi ML; Ong CK; Lim WK; Dima S; Pairojkul C; Lim KH; McPherson JR; Cutcutache I; Heng HL; Ooi L; Chung A; Chow P; Cheow PC; Lee SY; Choo SP; Tan IB; Duda D; Nastase A; Myint SS; Wong BH; Gan A; Rajasegaran V; Ng CC; Nagarajan S; Jusakul A; Zhang S; Vohra P; Yu W; Huang D; Sithithaworn P; Yongvanit P; Wongkham S; Khuntikeo N; Bhudhisawasdi V; Popescu I; Rozen SG; Tan P; Teh BT
Nat Genet; 2013 Dec; 45(12):1474-8. PubMed ID: 24185513
[TBL] [Abstract][Full Text] [Related]
23. Genetics of Opisthorchis viverrini-related cholangiocarcinoma.
Jusakul A; Kongpetch S; Teh BT
Curr Opin Gastroenterol; 2015 May; 31(3):258-63. PubMed ID: 25693006
[TBL] [Abstract][Full Text] [Related]
24. FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
Cristinziano G; Porru M; Lamberti D; Buglioni S; Rollo F; Amoreo CA; Manni I; Giannarelli D; Cristofoletti C; Russo G; Borad MJ; Grazi GL; Diodoro MG; Giordano S; Sacconi A; Forcato M; Anastasi S; Leonetti C; Segatto O
J Hepatol; 2021 Aug; 75(2):351-362. PubMed ID: 33741397
[TBL] [Abstract][Full Text] [Related]
25. FGF10/FGFR2 Signaling: Therapeutically Targetable Vulnerability in Ligand-responsive Cholangiocarcinoma Cells.
Oeurn K; Jusakul A; Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Kongpetch S
In Vivo; 2023; 37(4):1628-1637. PubMed ID: 37369494
[TBL] [Abstract][Full Text] [Related]
26. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.
Rizzo A
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34066684
[TBL] [Abstract][Full Text] [Related]
27. Inflammatory response to liver fluke Opisthorchis viverrini in mice depends on host master coregulator MTA1, a marker for parasite-induced cholangiocarcinoma in humans.
Nair SS; Bommana A; Pakala SB; Ohshiro K; Lyon AJ; Suttiprapa S; Periago MV; Laha T; Hotez PJ; Bethony JM; Sripa B; Brindley PJ; Kumar R
Hepatology; 2011 Oct; 54(4):1388-97. PubMed ID: 21725997
[TBL] [Abstract][Full Text] [Related]
28. Synopsis.
Khuntikeo N; Andrews RH; Petney TN; Khan SA
Recent Results Cancer Res; 2023; 219():361-367. PubMed ID: 37660340
[TBL] [Abstract][Full Text] [Related]
29. Targeting FGFR inhibition in cholangiocarcinoma.
Goyal L; Kongpetch S; Crolley VE; Bridgewater J
Cancer Treat Rev; 2021 Apr; 95():102170. PubMed ID: 33735689
[TBL] [Abstract][Full Text] [Related]
30. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.
Borad MJ; Gores GJ; Roberts LR
Curr Opin Gastroenterol; 2015 May; 31(3):264-8. PubMed ID: 25763789
[TBL] [Abstract][Full Text] [Related]
31. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
[TBL] [Abstract][Full Text] [Related]
32. FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune Signatures.
Sridharan V; Neyaz A; Chogule A; Baiev I; Reyes S; Barr Fritcher EG; Lennerz JK; Sukov W; Kipp B; Ting DT; Deshpande V; Goyal L
Clin Cancer Res; 2022 Dec; 28(24):5431-5439. PubMed ID: 36190545
[TBL] [Abstract][Full Text] [Related]
33. Current status of human liver fluke infections in the Greater Mekong Subregion.
Sripa B; Suwannatrai AT; Sayasone S; Do DT; Khieu V; Yang Y
Acta Trop; 2021 Dec; 224():106133. PubMed ID: 34509453
[TBL] [Abstract][Full Text] [Related]
34. Risk factors for cholangiocarcinoma in high-risk area of Thailand: role of lifestyle, diet and methylenetetrahydrofolate reductase polymorphisms.
Songserm N; Promthet S; Sithithaworn P; Pientong C; Ekalaksananan T; Chopjitt P; Parkin DM
Cancer Epidemiol; 2012 Apr; 36(2):e89-94. PubMed ID: 22189445
[TBL] [Abstract][Full Text] [Related]
35. Population-Based Intervention for Liver Fluke Prevention and Control in Meuang Yang District, Nakhon Ratchasima Province, Thailand.
Kompor P; Muang Karn R; Norkaew J; Kujapun J; Photipim M; Ponphimai S; Chavengkun W; Phong Paew S; Kaewpitoon S; Rujirakul R; Wakhuwathapong P; Phatisena T; Eaksanti T; Joosiri A; Polsripradistdist P; Padchasuwan N; Kaewpitoon N
Asian Pac J Cancer Prev; 2016; 17(2):685-9. PubMed ID: 26925664
[TBL] [Abstract][Full Text] [Related]
36. Potential targeted therapy for liver fluke associated cholangiocarcinoma.
Vaeteewoottacharn K; Seubwai W; Bhudhisawasdi V; Okada S; Wongkham S
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):362-70. PubMed ID: 24408866
[TBL] [Abstract][Full Text] [Related]
37. Ultrasound screening for Opisthorchis viverrini-associated cholangiocarcinomas: experience in an endemic area.
Mairiang E; Chaiyakum J; Chamadol N; Laopaiboon V; Srinakarin J; Kunpitaya J; Sriamporn S; Suwanrungruang K; Vatanasapt V
Asian Pac J Cancer Prev; 2006; 7(3):431-3. PubMed ID: 17059338
[TBL] [Abstract][Full Text] [Related]
38. Practical considerations in screening for genetic alterations in cholangiocarcinoma.
Bekaii-Saab TS; Bridgewater J; Normanno N
Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504
[TBL] [Abstract][Full Text] [Related]
39. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.
Sia D; Losic B; Moeini A; Cabellos L; Hao K; Revill K; Bonal D; Miltiadous O; Zhang Z; Hoshida Y; Cornella H; Castillo-Martin M; Pinyol R; Kasai Y; Roayaie S; Thung SN; Fuster J; Schwartz ME; Waxman S; Cordon-Cardo C; Schadt E; Mazzaferro V; Llovet JM
Nat Commun; 2015 Jan; 6():6087. PubMed ID: 25608663
[TBL] [Abstract][Full Text] [Related]
40. [Not Available].
Mas L; Perrier A; Coulet F; Bachet JB
Bull Cancer; 2022 Nov; 109(11S):11S28-11S34. PubMed ID: 36535760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
